



March 4, 2016

Senator Ron Wyden
Ranking Member, Finance Committee
219 Dirksen Senate Building
Washington, DC 20510

Senator Charles Grassley
Finance Committee
219 Dirksen Senate Building
Washington, DC 20510

Dear Senators Wyden and Grassley:

Thank you for the opportunity to provide information regarding the impact of high cost, breakthrough drugs on private and public payers as well as the American public.

New drugs such as Sovaldi and Harvoni represent a breakthrough in treatment for those living with diseases. The extremely high cost of these drugs and the potential for other drugs in the pipeline to be of equally high-cost when they come to market, raises serious questions about the ability of state and federal and private payers to afford such treatments in the long term.

At Molina Healthcare, our mission is to provide the best health care services to our members who are among the nation's most vulnerable. We are also committed to providing the best value to our partners - state and the federal government.

We appreciate your leadership in responding to the high cost of prescription drugs, particularly the impact on patient access and government sponsored programs including Medicaid.

Sincerely,

A handwritten signature in black ink, appearing to read 'K. Preede'.

Ken Preede
Associate Vice President,
Government Affairs

A handwritten signature in black ink, appearing to read 'Amy Tenhouse'.

Amy Tenhouse
Associate Vice President,
Government Affairs